ObjectivesTo assess the contraceptive efficacy, bleeding pattern and safety of a combined oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg.DesignMulticenter, open-label, phase 3 trial.SettingSixty-nine sites in Europe and Russia.PopulationSexually active women aged 18-50 years with regular menstrual cycles and body mass index ≤35 kg/m2 .MethodsE4/DRSP was administered in a 24 active/4 placebo regimen for up to 13 cycles. Visits were scheduled during Cycles 2, 4, 7 and 10 and after completing treatment during which adverse events (AEs) were collected. Participants recorded medication intake, vaginal bleeding/spotting, use of other contraceptive methods and sexual intercourse on a daily diary.Main outcome measure...
Purpose A new POP consisting of 4 mg drospirenone (DRSP) for 24 days with a 4-day hormone-free inter...
Estetrol (E4) is a natural estrogenic steroid that is normally produced by human fetal liver. Recent...
Objective: To assess the bleeding profile, acceptance and safety of an extended 126-day regimen of t...
Objectives To assess the contraceptive efficacy, bleeding pattern and safety of a combined oral cont...
Abstract Objectives: To assess the contraceptive efficacy, bleeding pattern and safety of a combine...
ObjectiveTo assess efficacy, cycle control, and safety of an oral contraceptive containing estetrol ...
ObjectivesTo evaluate tolerability and safety of estetrol (E4) 15 mg/drospirenone (DRSP) 3 mg oral c...
AbstractObjectivesThis study aims to assess vaginal bleeding patterns and cycle control of oral cont...
ObjectiveTo evaluate the bleeding patterns of a new combined oral contraceptive containing estetrol ...
ObjectiveTo evaluate overall and subgroup efficacy of an estetrol (E4) 15 mg drospirenone (DRSP) 3 m...
Objective: The study was conducted to assess the efficacy of a low-dose combined oral contraceptive ...
Objective: To evaluate and compare the contraceptive efficacy, bleeding pattern, side effects and ot...
BackgroundProgestin-only pills are associated with irregular bleeding pattern including amenorrhea. ...
Objective: To assess the effect on hemostasis parameters of a new combined oral contraceptive (COC)....
Objectives The aim of the study was to evaluate the efficacy of different dosages of estetrol (E4) c...
Purpose A new POP consisting of 4 mg drospirenone (DRSP) for 24 days with a 4-day hormone-free inter...
Estetrol (E4) is a natural estrogenic steroid that is normally produced by human fetal liver. Recent...
Objective: To assess the bleeding profile, acceptance and safety of an extended 126-day regimen of t...
Objectives To assess the contraceptive efficacy, bleeding pattern and safety of a combined oral cont...
Abstract Objectives: To assess the contraceptive efficacy, bleeding pattern and safety of a combine...
ObjectiveTo assess efficacy, cycle control, and safety of an oral contraceptive containing estetrol ...
ObjectivesTo evaluate tolerability and safety of estetrol (E4) 15 mg/drospirenone (DRSP) 3 mg oral c...
AbstractObjectivesThis study aims to assess vaginal bleeding patterns and cycle control of oral cont...
ObjectiveTo evaluate the bleeding patterns of a new combined oral contraceptive containing estetrol ...
ObjectiveTo evaluate overall and subgroup efficacy of an estetrol (E4) 15 mg drospirenone (DRSP) 3 m...
Objective: The study was conducted to assess the efficacy of a low-dose combined oral contraceptive ...
Objective: To evaluate and compare the contraceptive efficacy, bleeding pattern, side effects and ot...
BackgroundProgestin-only pills are associated with irregular bleeding pattern including amenorrhea. ...
Objective: To assess the effect on hemostasis parameters of a new combined oral contraceptive (COC)....
Objectives The aim of the study was to evaluate the efficacy of different dosages of estetrol (E4) c...
Purpose A new POP consisting of 4 mg drospirenone (DRSP) for 24 days with a 4-day hormone-free inter...
Estetrol (E4) is a natural estrogenic steroid that is normally produced by human fetal liver. Recent...
Objective: To assess the bleeding profile, acceptance and safety of an extended 126-day regimen of t...